Deals•Jun 1, 2026
CEPI Pledges $50M to Moderna for mRNA Ebola Vaccine Development
The Coalition for Epidemic Preparedness Innovations (CEPI) announced a $50 million commitment to Moderna for pre‑clinical development and Phase 1 testing of an mRNA vaccine against the Bundibugyo ebolavirus, with additional support for manufacturing scale‑up and Phase 2/3 trial preparation. The funding aims to accelerate vaccine development amid a raging outbreak in the Democratic Republic of the Congo.
